scispace - formally typeset
S

Sanjeev Shukla

Researcher at Indian Institute of Science Education and Research, Bhopal

Publications -  38
Citations -  2221

Sanjeev Shukla is an academic researcher from Indian Institute of Science Education and Research, Bhopal. The author has contributed to research in topics: Alternative splicing & RNA splicing. The author has an hindex of 13, co-authored 31 publications receiving 1846 citations. Previous affiliations of Sanjeev Shukla include Cancer Research Institute.

Papers
More filters
Journal ArticleDOI

CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing

TL;DR: This work provides the first evidence that a DNA-binding protein, CCCTC-binding factor (CTCF), can promote inclusion of weak upstream exons by mediating local RNA polymerase II pausing both in a mammalian model system for alternative splicing, CD45, and genome-wide.
Journal ArticleDOI

Apigenin and cancer chemoprevention: Progress, potential and promise (Review)

TL;DR: Appigenin has been shown to possess remarkable anti-inflammatory, antioxidant and anti-carcinogenic properties, and its considerable potential for development as a cancer chemopreventive agent is evaluated.
Journal ArticleDOI

TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing.

TL;DR: The methylcytosine dioxygenases TET1 and TET2 are revealed as active regulators of CTCF‐mediated alternative splicing through conversion of 5‐methylcyTosine to its oxidation derivatives, significantly expanding the current concept of the pre‐mRNA “splicing code” to include dynamic intragenic DNA methylation catalyzed by the TET proteins.
Journal ArticleDOI

Chamomile: An anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity

TL;DR: It is demonstrated that chamomile inhibits NO production and iNOS gene expression by inhibiting RelA/p65 activation and supports the utilization of chamamile as an effective anti-inflammatory agent.
Journal ArticleDOI

Single-Site Labeling of Native Proteins Enabled by a Chemoselective and Site-Selective Chemical Technology

TL;DR: The linchpin directed modification (LDM) provides a convenient route for the conjugation of a fluorophore and drug to a Fab and monoclonal antibody and delivers trastuzumab-doxorubicin andtrastuzuab-emtansine conjugates with selective antiproliferative activity toward Her-2 positive SKBR-3 breast cancer cells.